LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $105.80 Average Target Price from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $105.80.

Several equities research analysts have weighed in on the stock. Roth Mkm reiterated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Barrington Research upped their price objective on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Citizens Jmp raised their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $107.39 on Wednesday. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $2.45 billion, a P/E ratio of 42.78, a PEG ratio of 3.06 and a beta of 0.66. The business has a 50-day moving average of $89.29 and a 200-day moving average of $88.81. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period last year, the company posted $0.49 EPS. LeMaitre Vascular’s revenue for the quarter was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date is Thursday, March 12th. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.87%.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 8,464 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the transaction, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 215,438 shares of company stock worth $23,062,911. 9.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust raised its stake in shares of LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 287 shares during the period. Cornerstone Planning Group LLC lifted its holdings in shares of LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 283 shares in the last quarter. MAI Capital Management acquired a new position in shares of LeMaitre Vascular during the third quarter worth about $38,000. First Horizon Corp bought a new position in shares of LeMaitre Vascular during the third quarter worth about $39,000. Finally, Geneos Wealth Management Inc. grew its holdings in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.